Table 1.
Clinical characteristics of the study population.
| Abatacept (N = 15) | csDMARDs (N = 20) | P value | |
|---|---|---|---|
| Female, n (%) | 12 (80.0) | 17 (85.0) | > 0.99 |
| Age, years | 73.1 ± 8.7 | 63.2 ± 9.7 | 0.004 |
| Duration of RA, years | 5.0 ± 5.9 | 2.0 ± 5.0 | 0.006 |
| csDMARDs | MTX:18,TAC:1 SASP:1 | ||
| Concomitant MTX use, n (%) | 7 (46.7) | ||
| Concomitant oral steroid use, n (%) | 4 (26.7) | 7 (35.0) | 0.721 |
| Mean oral steroid dose (mg/day) | 2.25 ± 1.89 | 5.86 ± 1.86 | 0.018 |
| ACPA positive, n (%) | 12/13 (92.0) | 14/20 (70.0) | 0.198 |
| RF positive, n (%) | 12/13 (92.0) | 14/20 (70.0) | 0.198 |
| DAS28-ESR | 5.19 ± 1.57 | 5.01 ± 1.34 | 0.593 |
| CDAI | 20.5 ± 14.3 | 21.0 ± 10.2 | 0.913 |
Data are mean ± standard deviation (SD) unless otherwise indicated.
RA rheumatoid arthritis, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, MTX methotrexate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, DAS disease activity score, ESR erythrocyte sedimentation rate, CDAI clinical disease activity index.